IP Library Assignment 074994/0338
Patent Assignment
Reel/Frame 074994/0338

Second Amended and Restated Patent Security Agreement

Recorded: 2026-03-02 Pages: 45
Assignor
UROGEN PHARMA LTD.
Executed: 2026-02-26
Assignee
BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD, EXETER, EX4 4EP, UNITED KINGDOM
Covered Properties (44)
Treatment of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer with a Thermally Gelling Pharmaceutical Composition Containing Mitomycin
Application: 18/784,354 →
Publication: US 2025/0032409
Immunomodulating Treatments of Body Cavities
Application: 19/094,915 →
Publication: US 2025/0221929
Oncolytic Adenovirus Compositions with Enhanced Replication Properties
Application: 19/261,101 →
Publication: US 2026/0167940
Adenoviral Assembly Method
Application: 17/681,538 →
Publication: US 2022/0411763
Oncolytic Adenovirus Compositions
Application: 17/371,546 →
Publication: US 2022/0096577
High Throughput Assay for Measuring Adenovirus Replication Kinetics
Application: 18/809,603 →
Publication: US 2025/0146013
Exogenous Gene Expression in Recombinant Adenovirus for Minimal Impact on Viral Kinetics
Application: 19/097,089 →
Publication: US 2025/0382638
Tumor-Targeting Synthetic Adenoviruses and Uses Thereof
Application: 18/478,388 →
Publication: US 2024/0207445
Selective Cell Targeting Using Adenovirus and Chemical Dimers
Application: 18/426,803 →
Publication: US 2024/0342231
Hsv-1 Oncolytic Virus Therapies That Specifically Kill Alt Dependent Cancers
Application: 18/797,069 →
Publication: US 2025/0134941
Biocompatible Drug Delivery Apparatus and Methods
Patent: 8,361,490 →
Application: 10/941,942 →
Publication: US 2006/0057208
Pharmaceutical Compositions Comprising Imidazoquinolin(Amines) and Derivatives Thereof Suitable for Local Administration
Patent: 9,066,940 →
Application: 13/147,194 →
Publication: US 2011/0319442
Material and Method for Treating Internal Cavities
Patent: 9,040,074 →
Application: 13/553,198 →
Publication: US 2013/0046275
Phospholipid Drug Analogs
Patent: 9,173,936 →
Application: 13/772,235 →
Publication: US 2013/0267481
Phospholipid Drug Analogs
Patent: 9,180,183 →
Application: 13/772,253 →
Publication: US 2013/0266635
Pharmaceutical Compositions Comprising Imidazoquinolin(Amines) and Derivatives Thereof Suitable for Local Administration
Patent: 9,107,919 →
Application: 13/775,906 →
Publication: US 2013/0237561
Material and Method for Treating Internal Cavities
Application: 14/054,731 →
Publication: US 2014/0105884
Slow Release Formulations of Cell Cycle Regulators and Anti-Cancer Agents for Local Treatment of Solid Cancer
Patent: 9,801,854 →
Application: 14/600,354 →
Material and Method for Treating Internal Cavities
Application: 14/720,676 →
Publication: US 2015/0366974
Phospholipid Drug Analogs
Patent: 9,540,407 →
Application: 14/869,677 →
Publication: US 2016/0090395
Material and Method for Treating Internal Cavities
Patent: 9,950,069 →
Application: 15/366,256 →
Publication: US 2017/0112935
Immunomodulating Treatments of Body Cavities
Application: 16/297,839 →
Publication: US 2019/0201334
Material and Method for Treating Cancer
Application: 17/546,204 →
Publication: US 2022/0202773
Thermosensitive Bio-Adhesive Hydrogel for Removal of Ureteral and Renal Stones
Application: 17/703,238 →
Publication: US 2022/0304766
Material and Method for Treating Cancer
Application: 18/535,108 →
Publication: US 2024/0108603
Material and Method for Treating Internal Cavities
Application: 18/625,862 →
Publication: US 2024/0299550
Immunomodulating Treatments of Body Cavities
Application: 18/665,612 →
Publication: US 2024/0382420
Material and Method for Treating Internal Cavities
Application: 19/066,754 →
Publication: US 2025/0195665
Oncolytic Adenovirus with Enhanced Replication Properties Comprising Modifications in E1A, E3, and E4
Application: 17/067,496 →
Publication: US 2021/0024587
Adenoviral Assembly Method
Patent: 9,217,160 →
Application: 13/769,025 →
Publication: US 2013/0231267
Adenoviral Assembly Method
Application: 14/935,866 →
Publication: US 2016/0053235
Oncolytic Adenovirus Compositions
Application: 14/852,981 →
Publication: US 2015/0374766
Oncolytic Tumor Viruses and Methods of Use
Application: 15/468,565 →
Publication: US 2017/0202893
High Throughput Assay for Measuring Adenovirus Replication Kinetics
Application: 16/109,513 →
Publication: US 2018/0355374
Exogenous Gene Expression in Therapeutic Adenovirus for Minimal Impact on Viral Kinetics
Application: 16/110,207 →
Publication: US 2018/0355379
Exogenous Gene Expression in Recombinant Adenovirus for Minimal Impact on Viral Kinetics
Application: 16/916,764 →
Publication: US 2020/0325492
Exogenous Gene Expression in Recombinant Adenovirus for Minimal Impact on Viral Kinetics
Application: 17/852,891 →
Publication: US 2023/0088476
Tumor-Targeting Synthetic Adenoviruses and Uses Thereof
Application: 16/434,714 →
Publication: US 2019/0314523
Adenoviral Tumor Diagnostics
Patent: 9,885,090 →
Application: 14/485,488 →
Publication: US 2015/0005397
Anti-Cancer Adenoviruses
Patent: 9,187,733 →
Application: 13/768,933 →
Publication: US 2013/0243729
Selective Cell Targeting Using Adenovirus and Chemical Dimers
Patent: 9,913,866 →
Application: 14/485,472 →
Publication: US 2015/0017127
Hsv-1 Oncolytic Virus Therapies That Specifically Kill Alt Dependent Cancers
Application: 16/169,421 →
Publication: US 2019/0046594
Process for the Preparation of a Freeze-Dried Pharmaceutical Composition Containing Mitomycin C
Application: 16/876,505 →
Publication: US 2020/0276128
Process for the Preparation of a Freeze-Dried Pharmaceutical Composition Containing Mitomycin C
Application: 15/031,519 →
Publication: US 2016/0256391
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Sep 16, 2004
From: HOLZER, ASHER; DANIEL, DORIT; HIRSZOWICZ, ERAN
To: THERACOAT LTD.
Reel/Frame 015817/0081 →
Assignment of Assignor's Interest Sep 14, 2011
From: LEONI, LORENZO; MAJ, ROBERTO; PATTARINO, FRANCO; VECCHIO, CARLO
To: TELORMEDIX SA
Reel/Frame 026906/0392 →
Assignment of Assignor's Interest Nov 5, 2012
From: HOLZER, ASHER; DANIEL, DORIT; MULLERAD, MICHAEL; DE LA ZERDA, JAIME
To: THERACOAT LTD.
Reel/Frame 029238/0909 →
Assignment of Assignor's Interest Jun 20, 2013
From: MAJ, ROBERTO; PATTARINO, FRANCO; MURA, EMANUELA; BARBERIS, ALCIDE
To: TELORMEDIX SA
Reel/Frame 030655/0891 →
Assignment of Assignor's Interest Nov 3, 2013
From: LEONI, LORENZO; MAJ, ROBERTO; PATTARINO, FRANCO; VECCHIO, CARLO
To: TELORMEDIX SA
Reel/Frame 031533/0541 →
Assignment of Assignor's Interest Jan 9, 2014
From: KONORTY, MARINA; HAKIM, GIL
To: THERACOAT LTD
Reel/Frame 031947/0586 →
Assignment of Assignor's Interest Oct 27, 2015
From: MAJ, ROBERT; PATTARINO, FRANCO; MURA, EMANUELA; BARBERIS, ALCIDE
To: TELORMEDIX SA
Reel/Frame 036895/0721 →
Asset Purchase Agreement Nov 13, 2015
From: TELORMEDIX SA
To: THERACOAT LTD.
Reel/Frame 037109/0769 →
Change of Name Nov 13, 2015
From: THERACOAT LTD
To: UROGEN PHARMA LTD
Reel/Frame 037111/0567 →
Change of Name Nov 24, 2015
From: THERACOAT LTD.
To: UROGEN PHARMA LTD.
Reel/Frame 037135/0053 →
Change of Name Jan 19, 2016
From: THERACOAT LTD.
To: UROGEN PHARMA LTD.
Reel/Frame 037553/0678 →
Assignment of Assignor's Interest Feb 4, 2016
From: TELORMEDIX, SA
To: UROGEN PHARMA LTD.
Reel/Frame 037668/0353 →
Change of Name Jan 8, 2018
From: THERACOAT LTD.
To: UROGEN PHARMA LTD.
Reel/Frame 045016/0287 →
Assignment of Assignor's Interest Jan 8, 2018
From: HOLZER, ASHER; DANIEL, DORIT; MULLERAD, MICHAEL; DE LA ZERDA, JAIME
To: THERACOAT LTD.
Reel/Frame 044556/0637 →
Change of Name Mar 15, 2021
From: THERACOAT LTD.
To: UROGEN PHARMA LTD.
Reel/Frame 055588/0095 →
Security Interest Apr 8, 2021
From: UROGEN PHARMA LTD.
To: RTW INVESTMENTS ICAV
Reel/Frame 055868/0385 →
Assignment of Assignor's Interest Jul 12, 2021
From: O'SHEA, CLODAGH; MIYAKE-STONER, SHIGEKI
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 056830/0176 →
Assignment of Assignor's Interest Feb 25, 2022
From: O'SHEA, CLODAGH; POWERS, COLIN
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 059107/0939 →
Security Interest Mar 18, 2022
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 059302/0501 →
Amended and Restated Patent Security Agreement May 19, 2022
From: UROGEN PHARMA LTD.
To: RTW INVESTMENTS ICA V
Reel/Frame 060121/0591 →
Assignment of Assignor's Interest Oct 2, 2023
From: O'SHEA, CLODAGH; POWERS, COLIN; ZHANG, LEI
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 065088/0382 →
Patent Security Agreement Mar 18, 2024
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC
Reel/Frame 066805/0346 →
Assignment of Assignor's Interest Aug 9, 2024
From: O'SHEA, CLODAGH; DEHART, JASON
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 068240/0293 →
Assignment of Assignor's Interest Aug 20, 2024
From: O'SHEA, CLODAGH; PARTLO, WILLIAM; POWERS, COLIN
To: SALK INSTITUTE FOR BIOLOGICAL STUDIES
Reel/Frame 068340/0673 →
Amended and Restated Patent Security Agreement Mar 6, 2025
From: UROGEN PHARMA LTD.
To: BIOPHARMA CREDIT PLC [COLLATERAL AGENT]
Reel/Frame 070434/0319 →